BLAINJECTIONINJECTABLE
Approved
Aug 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERELZI is a biosimilar of etanercept, a TNF-receptor fusion protein approved in 2016 by Novartis. It treats nine autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, and vasculitis by blocking tumor necrosis factor signaling. The drug is administered via subcutaneous or intravenous injection.
Peak
ERELZI operates in a mature TNF-inhibitor market with moderate competitive pressure (30/100); career growth depends on biosimilar penetration strategy and market share capture from reference ENBREL.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Novartis is hiring 2 roles related to this product
Worked on ERELZI at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.